Nanotechnology in Stroke: New Trails with Smaller Scales

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Neurology

Background:

• Stroke is a major cause of death and disability, necessitating improved therapeutic interventions.
• Current treatments like tissue plasminogen activator (tPA) and endovascular thrombectomy (EVT) have limitations including narrow time windows and risks of hemorrhage.
• Ischemia-reperfusion injury and blood-brain barrier disruption are significant challenges following acute stroke treatment.

Purpose of the Study:

• To review advances in nanoparticle-based approaches for treating cerebrovascular conditions.
• To highlight the potential of nanoparticles as multifunctional thrombolytic agents.
• To explore the development of theranostic agents for improved stroke patient outcomes.

Main Methods:

• Review of current literature on nanoparticle applications in stroke therapy.
• Analysis of nanoparticle properties for targeted drug delivery and multifunctional capabilities.
• Exploration of theranostic nanoparticle designs combining therapeutic and diagnostic functions.

Main Results:

• Nanoparticles offer potential for thrombolytic agents with extended therapeutic windows and reduced side effects compared to tPA.
• Multifunctional nanoparticles can deliver thrombolytics along with neuroprotective, anti-inflammatory, or antioxidant agents.
• Theranostic nanoparticles integrating imaging capabilities alongside therapeutics are under development for enhanced stroke management.

Conclusions:

• Nanoparticle-based strategies represent a significant advancement in stroke treatment, addressing limitations of existing therapies.
• The development of multifunctional and theranostic nanoparticles holds great promise for improving clinical outcomes in stroke patients.
• Further research into nanoparticle delivery systems and safety profiles is crucial for clinical translation.